Ambrx Biopharma Inc. Appoints Janice Lu, M.D., Ph.D., as Chief Medical Officer
17 Mai 2022 - 10:05PM
Business Wire
Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage
biopharmaceutical company using an expanded genetic code technology
platform to create Engineered Precision Biologics (EPBs), today
announced the appointment of Janice Lu, M.D., Ph.D., as Chief
Medical Officer of Ambrx. Dr. Lu is a distinguished clinical
professor of medicine who has more than 18 years of experience in
leading clinical trials and breast cancer drug development.
“I am delighted to welcome Janice Lu to the Ambrx team and look
forward to leveraging her insight in breast oncology to continue to
progress ARX788 through the clinic,” said Feng Tian, Ph.D.,
Chairman of the Board, President, and CEO of Ambrx. “Janice has
been a valuable asset as a principal investigator for multiple
Ambrx trials, including the Phase 1 ACE-Pan Tumor-01 and Phase 2
ACE-Breast-03 clinical trials, and is the ideal candidate to take
the role of CMO at our company. I look forward to leaning on
Janice’s expertise to further our current research and development
efforts in the treatment of oncology.”
“I am impressed with the encouraging data from the ongoing
clinical trials of ARX788 and Ambrx’s engineered precision
biologics technology platform,” said Dr. Lu. “I am excited to begin
working with Ambrx in this new capacity, assisting with the ongoing
development of their clinical development pipeline and overseeing
the clinical operations. I believe our consorted efforts will
potentially provide therapeutic treatment options that are less
toxic and highly targeted to patients suffering from breast,
gastric, and other solid tumors.”
Dr. Lu has spent her career focused on managing the treatment of
women with breast cancer. Prior to her role at Ambrx, Dr. Lu was a
Clinical Professor of Medicine and Medical Director of the Breast
Oncology Program at the Keck School of Medicine, University of
Southern California Norris Comprehensive Cancer Center. Prior to
her role at USC, Dr. Lu was an Associate Professor of Clinical
Medicine in the Division of Hematology and Oncology at the
University of California, Los Angeles. Dr. Lu, a board certified
medical oncologist, began her career at SUNY Stony Brook where she
served as the Director of Breast Medical Oncology for several
years.
Dr. Lu received a M.D. from Peking University School of Medicine
as well as a Ph.D. from Syracuse University focusing on epigenetics
under the mentorship of Dr. David Allis (Rockefeller University).
Dr. Lu completed her Hematology and Oncology Fellowship at New York
University School of Medicine.
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical stage biopharmaceutical company using an
expanded genetic code technology platform to discover and develop
Engineered Precision Biologics. These include next generation
antibody drug conjugates (ADCs), bispecifics, targeted
immuno-oncology therapies, novel cytokines to modulate the immune
system, and long-acting therapeutic peptides for metabolic and
cardiovascular disease. Ambrx is advancing a robust portfolio of
clinical and preclinical programs designed to optimize efficacy,
safety and ease of use, in multiple therapeutic areas, including
its lead product candidate ARX788. In addition, Ambrx has clinical
collaborations with multiple partners, for drug candidates
generated using Ambrx technology. For more information, please
visit www.ambrx.com.
Forward-Looking Statements
This press release includes certain “forward-looking statements”
intended to qualify for the “safe harbor” from liability
established by the Private Securities Litigation Reform Act of
1995, as amended. Forward-looking statements may be identified by
the words “anticipate,” believe,” “estimate,” “expect,” “intend,”
“plan,” “project,” “may,” “will,” “could,” “should,” “seek,”
“potential” and similar expressions, and include, without
limitation, express or implied statements regarding Ambrx’s beliefs
and expectations regarding the advancement and potential benefits
of its product candidates, clinical development and strategic
plans. Forward-looking statements are based on Ambrx’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Factors that could cause
actual results to differ include, but are not limited to, those
risks and uncertainties associated with: the continuing impact of
the COVID-19 pandemic and other public health-related risks and
events on Ambrx’s business, operations, strategy, goals and
anticipated milestones; Ambrx’s ability to execute on its strategy
including with respect to the timing of its R&D efforts,
initiation of clinical trials and other anticipated milestones;
risks associated with development of novel therapeutics, including
potential delays in clinical trials and regulatory submissions and
the fact that future clinical trial results may not be consistent
with preliminary results or results from prior preclinical studies
or clinical trials; Ambrx’s ability to fund operations as
anticipated; and the additional risks and uncertainties set forth
more fully under the caption “Risk Factors” in Ambrx’s Annual
Report on Form 20-F filed with the United States Securities and
Exchange Commission (SEC) on April 26, 2022, and elsewhere in
Ambrx’s filings and reports with the SEC. Forward-looking
statements contained in this press release are made as of this
date, and Ambrx undertakes no duty to publicly update or revise any
forward looking statements, whether as a result of new information,
future events or otherwise, except as may be required under
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220517006174/en/
INVESTORS Laurence Watts Managing Director Gilmartin Group, LLC.
619-916-7620 ir@ambrx.com
MEDIA media@ambrx.com
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Mär 2023 bis Mär 2024